La plaga de lesiones defensivas obliga al FC Barcelona a moverse en el próximo mercado invernal. En cuestión de semanas, Hansi Flick se ha quedado sin Éric García, Koundé y Xavi Espart. Unas bajas que obligan al club a 'meter mano' en la próxima ventana de fichajes, que se abrirá en enero. Además de las lesiones, Flick busca recursos para su zaga defensiva. El tradicional debate sobre si el alemán debería modificar su metodología defensiva sigue estando muy presente en las bocas de la afición, y los tropiezos ante PSG y Real Madrid echan más leña al fuego.
Hansi Flick durante la rueda de prensa del postpartido ante el Real Madrid. Fuente: X
El central de 20 años del Stuttgart se posiciona como uno de los favoritos para la vacante. Finn Jeltsch se ha convertido en una de las revelaciones de la Bundesliga y el propio Hansi Flick está apretando para su incorporación, que rondaría los 50 millones de Euros. Destaca por ser un defensor físicamente potente, que con una estatura de 1,88 tiene buenas condiciones para los duelos aéreos y proteger su área. El germano reúne todas las características que le gustan a Hansi Flick, que conoce a la perfección el fútbol alemán, y su insistencia por la contratación del jugador no será casualidad. El Stuttgart tiene blindado a Jeltsch hasta 2030 y conoce el interés de otros grandes clubes de Europa, por lo que no será una operación sencilla.
El Argentino de 28 años acaba contrato con el Manchester United en 2027 y su renovación con el club está estancada. Desde Inglaterra aseguran que el deseo del futbolista es salir del país y ahí es donde se conoce el interés de clubes com0 el Atlético de Madrid. La operación se presenta como una oportunidad de mercado para Deco, quien no suele desperdiciarlas.
Ambos jugadores gustan mucho al staff. El club ya tanteó al Italiano el pasado verano, que finalmente no salió del Inter. En el caso del Croata, toda Europa permanece atenta a la situación del Manchester City y a las consecuencias del castigo por incumplir las normas del fair play financiero. No obstante, son operaciones más complicadas por el precio, que el Barça estudiaría ejecutarlas al finalizar la temporada.

#hansi

LONDON (AP) — Sarina Wiegman has signed a contract extension to stay as head coach of the England's women team through the 2029 European Championship, the FA said on Monday.
The Dutch coach, who will turn 57 later this month, led the Lionesses to a second straight Euros ****** le last year, having also steered the team to the World Cup final in 2023.
"I am so happy to be able to carry on with this squad and cannot think of a better job in football," she said. "Of course, anyone who knows me will understand that my main concern right now is absolutely the World Cup, and helping this squad realize their potential in the years to come."
Wiegman's previous deal was due to expire after the 2027 women's World Cup, which is scheduled to take place in Brazil next June. England will qualify for the tournament if it defeats Ukraine in a two-leg playoff, with the return game at Wembley Stadium on Dec. 5.
Wiegman, who was appointed as England coach in 2021, has reached five successive major tournament finals, having already claimed the European crown with the Netherlands in 2017.

#wiegman #european #tournament #london

England women's head coach Sarina Wiegman has signed a two-year contract extension taking her through until the end of the 2029 women's European Championship, the Football **** ociation announced Monday.
Wiegman has led England to tournament triumphs at both the 2022 and 2025 Euros, as well as a first World Cup final in 2023, since taking charge in September 2021.
The 56-year-old Dutchwoman has reached five successive major tournament finals, also winning Euro 2017 with her native Netherlands.
"I am so happy to be able to carry on with this squad and cannot think of a better job in football," Wiegman said Monday.
England, beaten by Spain in the 2023 World Cup final in Australia, will face Ukraine over a two-legged play-off in November and December for a place in next year's tournament in Brazil.

#england #year #taking #sarina

Sarina Wiegman has signed a two-year contract extension to remain England Women's head coach until the end of the 2029 European Championships.
The 56-year-old Dutch coach's contract with England was due to expire after next summer's Women's World Cup in Brazil.
The extension means Wiegman will remain in post through next summer's World Cup and Euro 2029, as well the 2027 Nations League campaign next spring which will serve as a qualification pathway for a Team GB squad at the 2028 Olympic Games in Los Angeles.
Wiegman's backroom staff, including Janneke Bijl and Arvid Smit, who joined after the 2025 Euros, will remain in post as well as long-standing goalkeeping coach Darren Ward.
It is the second contract extension of Wiegman's England tenure since her appointment in September 2021, having signed a new contract in 2024 after reaching the World Cup final with England in Australia and New Zealand.

#contract #next

Prince Harry, Duke of Sussex, has opened up about the impact of losing his mother, the late Princess Diana, at a young age.
The Prince has shared his journey with grief in a new Masterclass collaboration with neuroscientist Dr Mary-Frances O'Connor ****** led Redefining Grief: Building Resilience Through Loss.
In a video promoting the course, Harry discusses what it was like for him after his 36-year-old mother died in a car crash in Paris in 1997, revealing that he felt "emotionally numb" and spent years trying to cope.
"I couldn't remember my mum's laugh, couldn't remember what she looked like," he confided. "I felt like I had to be sad in order to prove to her that I missed her."
Prince Harry was 12 years old when his mother died. He later served for 10 years with the British Armed Forces, including two deployments to Afghanistan as an air controller and helicopter pilot.
"In my 20s, I went to war twice thinking I could outrun my feelings," he continued. "But that's not what happened. I'd spent so long emotionally numb to a large extent because ****** ody told me joy was still allowed, that it wasn't betrayal."

#prince #grief #emotionally

When Prince Harry first left the U.K., he didn't immediately adjust.
The Duke of Sussex, 42, teamed up with neuroscientist Dr. Mary-Frances O'Connor for a new MasterClass released on Thursday, October 8, ******* led Redefining Grief: Building Resilience Through Loss, in which viewers can "Discover new ways to process grief and loss so you can find your way back to you."
In the MasterClass, Harry recalled emotional turbulence after moving from England to Canada in late 2019 with his wife, Meghan Markle, and their son, Prince Archie, born in May 2019, People reported.
DMART/ZDS/Danny Martindale/WENN/Newscom/The Mega Agency
"Being in Canada, away from the stressful environment where presumably my body was just pumped full of adrenaline, within two or three days, I experienced this adrenaline crash, something that I'd never experienced before," Harry recounted. "It was as if I needed stress in order to get the adrenaline to make my brain function because I became useless around the house."

#harry #adrenaline #prince #masterclass

Prince Harry is opening up like never before about grief and what losing his mother, Princess Diana, at age 12 has meant for nearly every chapter of his life since.
In Redefining Grief: Building Resilience Through Loss, a new MasterClass available Oct. 8, the Duke of Sussex, 42, sits down with neuroscientist and grief expert Dr. Mary-Frances O'Connor for an intimate and at times deeply emotional conversation about loss, trauma and the ways grief can affect both the brain and body.
Rather than a traditional interview, the class — timed ahead of World Mental Health Day on Oct. 10 — unfolds as a candid exchange between Harry and O'Connor, a professor of clinical psychology and psychiatry at the University of Arizona whose research focuses on the psychological and physiological effects of bereavement. Together, they explore the science of grief and resilience while Harry draws extensively on his own life — from losing Diana and serving in Afghanistan to therapy, panic attacks, his marriage to Meghan Markle and life as a father.
"I didn't cry when I was told my mom died, only at her burial, and then not again for nearly two decades," he says near the start of the class. "I was convinced that was strength, but it wasn't. It was a 12-year-old boy with no permission to fall apart and no roadmap for how to heal."
"You would think I had the best help in the world. I'm a prince for God's sake, but I was still grieving and didn't have any place to put those feelings," he continues.

#harry #diana #loss #World

On September 17, Ferrari N.V. (NYSE:RACE) announced a partnership with the technology company Rakuten Group, Inc., effective January 1, 2027. The announcement gives no scope and no price tag, so it works better as a signal than as a number. The real substance sits in the results Ferrari posted on July 30, when it raised its 2026 guidance because buyers are ordering more personalization than the company expected.
In the second quarter, revenue rose 8%, but operating profit rose 10%, which means each euro of sales is leaving more behind. Ferrari credits a richer mix of cars, with the F80 helping, along with more buyers paying up for personalization. Strip out currency swings, and the gap widens, with revenue up 11% and operating profit up 16%. Deliveries of the Purosangue and the 296 Speciale family grew even in the middle of a planned model changeover.
Cash and demand back that up. Industrial free cash flow jumped 39% to €276 million, and Ferrari also returned more than €800 million to shareholders through a dividend and buybacks. Racing helped too, as higher sponsorships and engine rentals to other Formula 1 teams lifted revenue. Meanwhile, the order book covers 2027 in full, and the new 12Cilindri Manuale is already fully allocated, which is about as strong a demand signal as a carmaker can send. Those trends are why revenue guidance moved up to about €7.60 billion from about €7.50 billion.
Part of the strength is timing. Operating profit got a boost from temporarily lower depreciation and amortization while Ferrari swaps out models, and the company says those charges will climb once the new cars enter production. Net profit also leaned on a 23.0% tax rate, which reflects an estimated benefit from the new Patent Box. Neither says much about how profitable the cars themselves are.
Costs are climbing too. Higher industrial and marketing expenses weighed on operating profit, EBITDA margin slipped to 39.0% from 39.7% a year earlier, and management expects heavier brand, racing and digital spending for the year. Currency is a drag as well, mostly from the dollar and the yen, which is why 11% growth at constant currency shrank to 8% as reported. Deliveries totaled 3,366 cars while the 296 GTS, Roma Spider and SF90 XX family wound down, and sponsorship, commercial and brand revenue grew just 2%. And the whole outlook leans on current visibility into the Middle East crisis, which Ferrari cannot control.

#Ferrari

Shoulder-season travel is giving some hotels opportunities to trade for longer and reduce their dependence on peak months. But additional demand only changes the investment proposition if those extra trading periods generate durable profit and improve the quality of annual cash flow.
Across parts of Europe, tourism demand is becoming less concentrated in traditional peak periods.
The shift should not be overstated. July and August still accounted for 31.1% of all EU tourist-accommodation nights in 2025, according to Eurostat. In highly seasonal markets, the concentration was much greater: 54.5% of Croatia's annual nights and 41.6% of Greece's occurred during those two months.
But demand is moving at the margins. The European Travel Commission reported stronger autumn demand in several markets in late 2025. In Hungary, for example, growth in international arrivals and nights during autumn exceeded summer growth.
For hotel investors, however, a longer potential travel season is only the starting point.

#season

Biogen Inc. (BIIB) is a global biotechnology company that develops and commercializes therapies for serious and complex diseases. Headquartered in Cambridge, Massachusetts, Biogen has built a strong presence in neurology, specialized immunology, and rare diseases, with a portfolio spanning multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, ALS, and other conditions.
Companies worth $10 billion or more are typically classified as "large-cap stocks," and Biogen, with a market cap of $32.1 billion, fits the label perfectly. Biogen's core strength lies in its deep neuroscience expertise and a portfolio of established therapies for complex neurological and rare diseases. Its long-standing research capabilities, specialized commercial infrastructure, and broad pipeline also provide scale and expertise that smaller biotech rivals can find hard to replicate.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
Nvidia CEO Jensen Huang Just Dropped Huge News for This Cybersecurity Stock
How to Play GME Stock as GameStop CEO Ryan Cohen Buys $20.3 Million in Shares

#biogen #complex #expertise

Apollo Global Management, Inc. (NYSE:APO) is reportedly in talks to acquire Johnson & Johnson (NYSE:JNJ) DePuy Synthes orthopedics business in a transaction that could value the unit at close to $20 billion, according to Bloomberg, as reported by Reuters. J&J generated $9.3 billion of revenue from the orthopedics business in 2025, making the potential transaction material for both companies. The discussions could reach an agreement within weeks, although J&J is also considering a public-market spin-off. This is consistent with J&J's October 2025 decision to separate DePuy Synthes within an expected 18-to-24-month timeframe and shift its MedTech portfolio toward higher-growth, higher-margin businesses.
For Apollo Global Management, Inc. (NYSE:APO), the attraction is the opportunity to acquire a large, established medical-device franchise with substantial recurring demand from joint-replacement and surgical procedures. A roughly $20 billion valuation against $9.3 billion of 2025 revenue implies a price-to-sales multiple of about 2.2x, giving Apollo room to pursue operational improvements, portfolio rationalization, and margin expansion if the business is acquired at an attractive valuation.
DePuy Synthes also has meaningful scale and leading positions across major orthopedics categories, while J&J has recently invested in technologies that could strengthen the franchise, including an agreement covering Gemtrack tracking technology for robotic and navigation-assisted joint procedures and the acquisition of Expanding Innovations for expandable spine implants. Apollo is also entering the potential deal from a position of considerable financial scale: it had approximately $1.05 trillion of ***** ets under management as of June 30, 2026, with $198 billion in equity strategies and $849 billion in credit strategies. Its second-quarter results included $111 billion of gross capital deployment, demonstrating the capacity to execute large transactions.
For Johnson & Johnson (NYSE:JNJ), a sale could accelerate the portfolio transformation that management has already identified as a strategic priority while potentially delivering a sizeable upfront cash inflow. J&J explicitly said its planned orthopedics separation should increase the company's top-line growth and operating margins by allowing it to concentrate on Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision.
The company has also been restructuring orthopedics, with $307 million of restructuring expense in 2025, following $167 million in 2024 and $319 million in 2023, primarily tied to market and product exits. A sale could therefore remove a business that has required restructuring resources while allowing J&J to redeploy capital toward areas it views as higher growth and higher margin.

#billion #depuy

Apollo Global Management, Inc. (NYSE:APO) is reportedly in talks to acquire Johnson & Johnson (NYSE:JNJ) DePuy Synthes orthopedics business in a transaction that could value the unit at close to $20 billion, according to Bloomberg, as reported by Reuters. J&J generated $9.3 billion of revenue from the orthopedics business in 2025, making the potential transaction material for both companies. The discussions could reach an agreement within weeks, although J&J is also considering a public-market spin-off. This is consistent with J&J's October 2025 decision to separate DePuy Synthes within an expected 18-to-24-month timeframe and shift its MedTech portfolio toward higher-growth, higher-margin businesses.
For Apollo Global Management, Inc. (NYSE:APO), the attraction is the opportunity to acquire a large, established medical-device franchise with substantial recurring demand from joint-replacement and surgical procedures. A roughly $20 billion valuation against $9.3 billion of 2025 revenue implies a price-to-sales multiple of about 2.2x, giving Apollo room to pursue operational improvements, portfolio rationalization, and margin expansion if the business is acquired at an attractive valuation.
DePuy Synthes also has meaningful scale and leading positions across major orthopedics categories, while J&J has recently invested in technologies that could strengthen the franchise, including an agreement covering Gemtrack tracking technology for robotic and navigation-assisted joint procedures and the acquisition of Expanding Innovations for expandable spine implants. Apollo is also entering the potential deal from a position of considerable financial scale: it had approximately $1.05 trillion of **** ets under management as of June 30, 2026, with $198 billion in equity strategies and $849 billion in credit strategies. Its second-quarter results included $111 billion of gross capital deployment, demonstrating the capacity to execute large transactions.
For Johnson & Johnson (NYSE:JNJ), a sale could accelerate the portfolio transformation that management has already identified as a strategic priority while potentially delivering a sizeable upfront cash inflow. J&J explicitly said its planned orthopedics separation should increase the company's top-line growth and operating margins by allowing it to concentrate on Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision.
The company has also been restructuring orthopedics, with $307 million of restructuring expense in 2025, following $167 million in 2024 and $319 million in 2023, primarily tied to market and product exits. A sale could therefore remove a business that has required restructuring resources while allowing J&J to redeploy capital toward areas it views as higher growth and higher margin.

#NYSE #johnson

"He knows his role in the team. Serhou Guirassy is our number one striker. He is the challenger." With these clear words, Niko Kovač made it plain at the press conference ahead of the season opener against Hamburger SV who is in charge in Dortmund's attack. But in football, two weeks can feel like an eternity. By now, the black-and-yellow world looks very different.
Because Fabio Silva has now become so important that he could even prompt a system change at Dortmund. Guirassy himself also raved about his competitor. "Fabio Silva and I really enjoy playing together and we have a lot of fun in training. He is a great player," he said after the Champions League win against Villarreal to the microphone of 'Amazon Prime'.
You can see what else the two say about each other here in the video.
Coach Kovač was also full of praise after the win against the Spaniards. Fabio Silva repeatedly worked his way into clear-cut chances and rewarded himself for his effort. "You can see that we can play this system with two strikers just as well as with one striker. If we now add Fabio (Silva, editor's note) alongside Serhou (Guirassy, editor's note) too - and we will - then we really have something special," said the BVB coach happily.
Few would probably have expected the Portuguese forward to be receiving this kind of praise right now. In the summer, there were rumors about a transfer because Silva had only rarely been able to meet expectations. According to 'Sky', the Bundesliga club would have been open to talks starting at a fee of 20 million euros. Both a loan and a sale were reportedly considered.

#serhou #coach #clear #himself

The birth certificate?
This Friday evening, Fiorentina traveled to Venice for the fourth Serie A matchday after suffering nothing but defeats at the start of the season.
This time, La Viola could count on one of their new signings to carry them to victory.
On loan from Real Madrid, Franco Mastantuono grabbed a stunning hat-trick, including two goals in the ***** e of a single minute (29th, 30th, 84th).
These were the very first Serie A goals for the 19-year-old Argentine, who had been signed by Real from River Plate for 45 million euros in the summer of 2025.

#viola

A full day came down the final hole Friday in the 20th Solheim Cup.
And, once again, Carlota Ciganda delivered.
Wide off the tee on the par-4 18th and even farther right with her second shot, the 2023 Finca Cortesin hero, saved par from 12 feet to tie her match and keep the overall competition even entering Day 2.
Europe and the U.S. are knotted, 4-4, after the opening two sessions at Bernardus Golf in the Netherlands. In danger of falling behind on home turf, Ciganda added to her Solheim legend in teaming with fellow Spaniard Julia Lopez Rameriz, a cup rookie, to secure an improbable tie against Nelly Korda and Lauren Coughlin.
The sides split the morning foursomes, with the U.S. capturing the first two matches and the Euros claiming the latter two.

#cortesin #Europe

Interested in AbbVie Inc.? Here are five stocks we like better.
SKYRIZI and RINVOQ remain AbbVie's main growth drivers, with additional opportunities in inflammatory bowel disease, vitiligo, alopecia and hidradenitis suppurativa. The company expects a subcutaneous SKYRIZI induction approval for Crohn's disease in the fourth quarter and plans further combination-therapy data.
AbbVie is advancing a broad pipeline, including the BCMA-directed cancer therapy etentamig, which showed strong early multiple-myeloma results and could support a rapid regulatory filing. Neuroscience programs such as bretisilocin for depression are also expected to deliver additional data this year.
The company is taking a selective approach to acquisitions and partnerships, having invested about $20 billion in roughly 30 transactions while increasing annual R&D spending toward $10 billion. Management maintained its outlook for high-single-digit annual revenue growth through the decade.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

#disease #company #Therapy

Medtronic (NYSE: MDT), one of the world's largest medical device makers, was once considered a stable blue chip stock. But over the past five years, it has declined by more than 30% due to supply chain constraints, higher costs, quality control issues, and competitive pressure. However, Medtronic's stock is worth buying again for four simple reasons.
In fiscal 2026 (which ended this April), Medtronic's revenue grew 8.4% (and 5.8% organically) to $36.4 billion, marking its strongest top-line growth in ten years.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
That acceleration was driven by 9.3% organic growth in its cardiovascular business, which accounted for more than 38% of its enterprise revenue. All of its other segments (neuroscience, medical surgical, and diabetes) also grew organically.
Medtronic expects its organic revenue to rise 7.25%-7.75% in fiscal 2027, representing another multi-year high and easily exceeding its historical average of around 5%. Once again, that growth will be led by its rising sales of cardiovascular devices. From fiscal 2026 to fiscal 2029, ****** ysts expect its reported revenue to grow at a 5% CAGR.

#fiscal #NVIDIA

With a market cap of $138.2 billion, Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company that discovers, develops, manufactures, and markets innovative medicines worldwide. Its portfolio spans key therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, with well-known products such as Opdivo, Eliquis, Revlimid, and Yervoy.
Companies valued at $10 billion or more are generally classified as "large-cap" stocks, and Bristol-Myers Squibb fits this criterion perfectly. The company serves patients through a broad commercial network that includes wholesalers, distributors, specialty pharmacies, hospitals, clinics, and government agencies.
Nvidia CEO Jensen Huang Says His $3.5 Billion MediaTek Deal Is 'Not Circular' Because 'They Do Their Own Business'
Strategy's Strategy Appears to Have Failed, and the Outlook of MSTR Stock Is Unfavorable
A Potential ***** eX Deal Could Meaningfully Accelerate Growth for Technip Stock

#company #bristol #squibb #Stock

Money, money.
Elliott Anderson, Ayyoub Bouaddi, Enzo Fernandez & co.: Manchester City pulled off this summer the most expensive transfer window in football history, with 526 million euros spent. Quite simply.
The Everest of the spendthrift trend in English football in recent years.
Proof with this top 10 of the most expensive transfer windows in history, by club:
10) Newcastle - Summer 2026 transfer window - 301 million euros spent

#euros

SCARDOVARI, Italy (AP) — Italian fishermen for two years incinerated most of the invasive Atlantic blue crabs caught in the Po River Delta south of Venice. Few Italians had an appetite for the alien predator blamed for decimating their prized Manila clams.
While experiments in containment continue, including the release of tens of thousands of octopus predators, the industry's response has been shifting to find new markets for the crustaceans. The strategy is already salvaging the livelihood of some fishermen and, some hope, may even rehabilitate the much-maligned crab's image in Italy.
Like other members of his local cooperative, second-generation fisherman Federico Zago saw his income crash after the crab invasion. The Polesine Fishermen's Cooperative Consortium's revenues fell 75% to 15 million euros ($17 million) in 2024 and 2025; the cooperative's active members also shrank from 1,500 to 850.
"We needed to change strategy, and create an opportunity from this disaster," said Paolo Mancin, the cooperative's president.
Desperate, they pivoted to exporting the unwanted crabs, with the aim of preserving the Manila clams — invasive themselves — and mussels that created decades of prosperity in the shallow lagoons of Veneto and Emilia Romagna.

#manila #million

Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure.
Many crypto platforms let you trade digital coins and not much else. Uphold takes a wider swing by letting you trade more than 250 cryptocurrencies, four precious metals, and dozens of national currencies. It even allows you to directly trade one for another.
What makes that possible is what Uphold calls its anything-to-anything model, which moves you directly from bitcoin to gold, or from silver to euros, without forcing a sale in dollars in between. Very few platforms work this way.
That wide selection costs you, though. Uphold folds its fee into a spread on every trade, so the price you see already includes its cut, and that all-in price runs higher than several rivals. You also won't find the advanced trading tools that active traders use or any stocks and exchange-traded funds (ETFs).
Let's take a closer look at what Uphold delivers and where it falls flat based on our hands-on testing.

#uphold #platforms #directly

Sunderland are set to beat Crystal Palace to the signing of Malick Fofana from Lyon for 30m euros (£25.7m).
Sunderland had agreed a deal earlier before Palace made their own proposal, but the Black Cats are expected to sign the 21-year-old Belgium winger.
The deal is understood to now be at the paperwork stage.
Fofana is understood to be excited by the prospect of joining Sunderland before their first European campaign in 51 years, having qualified for the Europa League, although Palace have also qualified for the same competition.
Arsenal also attempted to sign Fofana, but the Premier League champions were unable to agree a fee with Lyon.

#understood

Juventus have announced the arrival of Pape Matar Sarr from Tottenham on an initial loan while also agreeing a season-long loan deal for Newcastle forward Nick Woltemade.
The Serie A club will pay Spurs about 2.5m euros (£2.1m) for the loan of Senegal midfielder Sarr.
The club confirmed the deal includes an obligation to buy the 23-year-old for 27.5m euros (£23.6m) if certain conditions are met during the 2026-27 season.
Sarr, who joined Spurs from Metz in 2021, made more than 100 Premier League appearances for the north London club and also helped them win the Europa League in 2025.
He has made 42 appearances for Senegal since his international debut in 2021 and won the Africa Cup of Nations in 2022.

#SPURS

Former Aston Villa and France winger Moussa Diaby has rejoined Bayer Leverkusen from Saudi side Al-Ittihad on a deal until 2031, the German club announced on Tuesday.
German tabloid Bild said Leverkusen paid 27 million euros ($31 million) to Al-Ittihad to bring Diaby, 27, back to the BayArena.
"When the request came and the move was possible, I didn't doubt it for a second," Diaby said in a statement, adding "the club has gotten bigger in the meantime -- aiming for **** les with Leverkusen is a very big goal of mine."
A fast winger, Diaby scored 31 goals and laid on 37 **** ists in 125 Bundesliga matches for Leverkusen after joining from Paris Saint-Germain in 2019.
He made his France debut while at Leverkusen and went on to gain 11 caps for the two-time world champions, last playing before the 2024 Euros.

#ittihad #million #former

North Chicago, Illinois-based AbbVie Inc. (ABBV) is a global, research-driven biopharmaceutical company focused on developing and commercializing medicines for complex and serious diseases. Valued at a market cap of $386.3 billion, its key therapeutic areas include immunology, neuroscience, oncology and aesthetics, with operations spanning more than 75 countries.
Companies with a market capitalization of $200 billion or more are typically referred to as "mega-cap stocks." ABBV fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the general drug manufacturers industry. AbbVie combines a large established pharmaceutical portfolio with a rapidly expanding immunology franchise and a broad pipeline.
Wu-Tang Clan Member Raekwon Is a Palantir 'OG,' Visiting Headquarters 16 Years After Receiving His Custom PLTR Jacket
Tesla Just Killed Its Solar Roof After Years of Struggling to Scale. What It Means for TSLA Stock.
Tesla Stock Could Benefit as Trump Locks Down the U.S. Power Grid

#abbvie #abbv #billion

Aug 30 (Reuters) - Ukraine's former defence minister Mykhailo Fedorov is ‌seeking U.S. investment for a ‌defence technology fund, he said in an interview with the Financial Times that was published on Sunday.
Fedorov is also seeking Western capital to build ‌and manage ⁠weapons development companies that he said will help Kyiv ⁠resist Moscow, the Financial Times said.
The former defence minister did not say whether he would benefit financially from ‌the fund, nor did he give details on his role overseeing it, according to the FT.
Meanwhile Ukraine's new defence minister, Yevhenii Khmara, ‌said Kyiv would seek to bring forward part of a €45 billion ($52.1 billion) loan ‌from the European Union planned for next year, as well as lobbying allies for greater contributions and new ‌countries that had not yet given.
($1 = 0.8634 euros)

#defence #financial #kyiv #seeking

Barcelona are closing in on a move for **** nal striker Gabriel Jesus in deal worth £8.6m (10m euros).
A deal for the Brazil international is believed to be at an advanced stage and, while the finer details still require finalising, the transfer is expected to be completed before Tuesday's deadline.
Napoli had shown an interest in Jesus, but the striker is set to join last season's Spanish league champions and will travel for a medical on Monday.
More to follow.
Find all the latest football transfers on our dedicated page

#deal #napoli

Diane Parry never expected to be the champion of WTA Monterrey, but after a grueling battle with Elise Mertens in the final, it's the Frenchwoman who emerged as champion in Mexico's Sultan of the North.
After a 6-4 0-6 6-3 win over Elise Mertens in the final, Diane Parry spoke on court about how she didn't have the highest of expectations entering the Abierto GNP Seguros, WTA Monterrey, saying "I came here last minute with almost nothing and didn't know what to expect"
Parry's ability to strike the ball from the baseline and work out of difficult situations showed the 23-year-old can win matches anywhere, as she bounced back from being bageled in the second set to focus in and get past the veteran Mertens. Parry also showcased a great one-handed backhand. Some of her best shotmaking came after she took a medical timeout in the second set and needed medical attention to her lower back.
Mertens weakness in the final? Break point conversion, as Parry saved 12 of the 17 she faced,
Diane Parry WTA Cincinnati Photo Credit: IMAGN IMAGES via Reuters Connect

#diane

NOVI SAD, Serbia (AP) — Small boats stand idle on cracked ground in a shriveled side channel of the Danube River in northern Serbia, where the water has receded into a couple of shrinking ponds under pressure from extreme drought and heat. Fish circle in the shallow waters.
"This is all we have, these two little ponds that are full of juvenile fish," fisherman Dusan Jovanovic said. He said the fish are in danger because there is too little water and its temperature is over 30 degrees Celsius (86 degrees Fahrenheit).
"If they start to die, they will all die at once," Jovanovic said.
Persistent drought and scorching heat this summer have ravaged ecosystems and businesses across the region, from a lake in Slovenia and the side channel of the Danube in Serbia, to fish farms in Bosnia, the Czech Republic, Romania and Hungary.
The fish industry has been hit especially hard, with damage estimated in the millions of euros (dollars). This is adding to the already high toll caused by problems with energy and water supplies, devastated crops, losses in river traffic and trade.

#serbia #ponds

Hormone therapy may protect a woman's aging brain, but timing is critical.
Experts agree the "window of opportunity" for HRT is typically in the late 40s or early 50s.
"Early intervention promotes and sustains brain health," neuroscientist Roberta Brinton said.
Get in there early. That seems to be the growing consensus around hormone replacement therapy (HRT) for women.
New study data suggests that middle-aged women could use these treatments to protect their brains, contradicting old concerns about a potential dementia risk.

#brain #women